dual agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
=== Physical and atomic === Roentgenium is expected to be a solid under normal conditions and to crystallize in the body-centered cubic structure, unlike its lighter congeners which crystallize in the face-centered cubic structure, due to its being expected to have different electron charge densities from them. It should be a very heavy metal with a density of around 22–24 g/cm3; in comparison, the densest known element that has had its density measured, osmium, has a density of 22.61 g/cm3. The atomic radius of roentgenium is expected to be around 114 pm.
=== Research === Psychiatric research is, by its very nature, interdisciplinary; combining social, biological and psychological perspectives in attempt to understand the nature and treatment of mental disorders. Clinical and research psychiatrists study basic and clinical psychiatric topics at research institutions and publish articles in journals. Under the supervision of institutional review boards, psychiatric clinical researchers look at topics such as neuroimaging, genetics, and psychopharmacology in order to enhance diagnostic validity and reliability, to discover new treatment methods, and to classify new mental disorders. Another thing to consider in research and conducting research in the field of psychiatry is the patients needs and values as Brock mentions their chapter on Informed Consent regarding the need to explain and inform participants about a research study and also act in their best interests, as Hellman and Hellman discuss. This can face challenges, such as dual-conflict roles in which their conflict roles between being a doctor and a researcher, especially in research involving control groups where some participants are not getting a treatment, where treating people as a merely just a means to an end, as discussed in Kantian morals, and not prioritizing their well-being and ensuring they are informed and given the option of treatments available, even those in research with positive predicted outcomes.
Haji-Sheikh, Haji-Sheikh & Naples (2026) present new cranial endocasts of Smilodon fatalis, and calculate that the range of brain endocast volumes of the studied species overlaps with the published range of brain volumes of modern lions. Evidence of utility of CT and MicroCT scans in determining the condition of tooth sockets in skulls of Smilodon fatalis from the La Brea Tar Pits, as well as in determining whether the canines of the studied specimens were correctly associated and correctly seated in tooth sockets during restoration of the skulls, is presented by Haji-Sheikh, Haji-Sheikh & Naples (2026). Schmökel, Del Chicca & Hagen Argudin Pina (2026) identify pathologies in three vertebrae of Smilodon fatalis from the La Brea Tar Pits, interpreted as consistent with the diagnosis of a spinal nerve tumor. Fernández-Jalvo et al. (2026) identify tooth marks of Smilodon on bones of Toxodon, Notiomastodon, Doedicurus, Glossotherium and Lestodon from the Pleistocene strata from the Salto de Piedra site (Argentina). A felid mandible interpreted as the most definitive fossil material of Homotherium latidens from Anatolia reported to date is described from the Burdur Basin (Turkey) by Yavuz et al. (2026). Nikolskiy et al. (2026) report the discovery of canines of Homotherium in the late Pleistocene strata from Suruktakh in the Kolyma River basin and from the Bolshoy Lyakhovsky Island (Russia), comfirming presence of members of this genus in northeastern Siberia approximately 41,500–37,500 years ago.
Headgear called a "scrum cap" in rugby, or simply "headgear" or ear guard in wrestling and other martial arts, that protects the ears is worn to help prevent this condition. A specialty ear splint can also be made to keep the ear compressed, so that the damaged ear is unable to fill thus preventing cauliflower ear. For some athletes, however, a cauliflower ear is considered a badge of courage or experience.
The tiger rattlesnake (Crotalus tigris) has a comparatively low venom yield but is considered to have the most toxic of all rattlesnake venoms, and the highest venom toxicity of all snakes in the Western Hemisphere. Although reluctant to bite, tiger rattlesnakes are known to be cantankerous and aggressive. Because of their tendency to stand their ground and aggressively defend themselves, they pose a serious threat to humans. Tiger rattlesnake venom has a high neurotoxic fraction that is antigenically related to Mojave toxin (see Crotalus scutulatus, venom A), and includes another component immunologically identical to crotamine, a myotoxin also found in tropical rattlesnakes (see Crotalus durissus). The venom has low but significant protease activity, although there does not seem to be any hemolytic activity. Brown (1973) lists an average venom yield of 11 mg (dried venom) and LD50 values of 0.07 mg/kg IP, 0.056 mg/kg IV, and 0.21 mg/kg SC. Minton and Weinstein (1984) list an average venom yield of 6.4 mg (based on two specimens). Weinstein and Smith (1990) list a venom yield of 10 mg. Humans are rarely bitten by the tiger rattlesnake, and literature available on bites by this snake is scarce. The several recorded human envenomations by tiger rattlesnakes produced little local pain, swelling, or other reaction following the bite and, despite the toxicity of its venom, no significant systemic symptoms have been recorded.
Sources: en.wikipedia.org
== South America == In June 2026, three Brazilian sisters with a combined age of 313, were recognized by Guinness as the oldest living trio of siblings in the world. The sisters, 103, 104 and 106 years old live, in Rio de Janeiro. They were discovered through a global organization that verifies longevity records, called LongeviQuest. Researchers are interested in not only the environmental, but also the genetic components that contribute to longevity. Ben Meyers, the CEO of LongeviQuest stated "When sisters reach that age, there is clearly a strong genetic component. But because they live near each other, they also have a support network, with family able to help when needed. There is definitely a community aspect as well."
== Treatment == There are many causes of necrosis, and as such treatment is based upon how the necrosis came about. Treatment of necrosis typically involves two distinct processes: Usually, the underlying cause of the necrosis must be treated before the dead tissue itself can be dealt with.
Hon Lik registered a patent for the modern e-cigarette design in 2003. Hon is credited with developing the first commercially successful electronic cigarette. The e-cigarette was first introduced to the Chinese domestic market in 2004. Many versions made their way to the US, sold mostly over the Internet by small marketing firms. E-cigarettes entered the European market and the US market in 2006 and 2007. The company that Hon worked for, Golden Dragon Holdings, registered an international patent in November 2007. The company changed its name to Ruyan (如烟, literally "like smoke") later the same month, and started exporting its products. Ruyan later changed its company name to Dragonite International Limited. Many e-cigarette makers copied his designs illegally, so Hon didn't receive all of the financial reward for his invention. In 2009 his company successfully sued a competitor in China, and after getting a US patent in 2012, they launched patent infringement lawsuits against multiple US companies. In 2013 his company sold its e-vapor business to Imperial Brands for 75 million USD. As of 2014, most e-cigarettes used a battery-powered heating element rather than the earlier ultrasonic technology design. Initially, their performance did not meet the expectations of users. The e-cigarette continued to evolve from the first-generation three-part device. In 2007, British entrepreneurs Umer and Tariq Sheikh invented the cartomizer. This is a mechanism that integrates the heating coil into the liquid chamber.
Drug Delivery: Developing Countries The drug delivery mechanisms have the potential to enhance the health of all parts of the world despite the fact that most of the advanced systems are quite costly to the poor nations. Simple system, orals or skin patch, is more feasible in low resource countries. Most countries have used vaccines that are administered orally to combat such diseases as polio (Yenet et al., 2023). The government and the hospital organizations need to collaborate in order to reduce the cost and offer the new means of drug distribution that will allow giving the new medications everywhere. Ethical and Safety Issues Emerging drug delivery devices such as nanoparticles or gene therapies are highly dangerous in terms of safety and equity. For example, we should make sure that the treatments would not negatively affect the environment or cause any incidental side effects. The regulation of other agencies such as FDA are applied in the process of ensuring the safety of new practices but vary across countries (World Health Organization, 2024). The government has the mandate of making sure that medicine is not only affordable to the wealthy members of the society, but also to the vulnerable ones as well. The issue of drug delivery has raised a number of ethical concerns with respect to patients and healthcare systems. One common concern is the accessibility of specific medications within a health organization.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.